Evaluation of the Cost Saving Potential of Introducing an Etanercept Biosimilar (SB4) for the Treatment of Approved Etanercept Indications in the Republic of Ireland
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.741
https://www.valueinhealthjournal.com/article/S1098-3015(17)31075-6/fulltext
Title :
Evaluation of the Cost Saving Potential of Introducing an Etanercept Biosimilar (SB4) for the Treatment of Approved Etanercept Indications in the Republic of Ireland
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)31075-6&doi=10.1016/j.jval.2017.08.741
First page :
A529
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
706